On July 22, 2020, Encoded Therapeutics announced that it has raised $135 million in an oversubscribed Series D financing. Wilson Sonsini represented Encoded Therapeutics in the transaction.

Encoded Therapeutics is a biotechnology company developing precision gene therapies for a broad range of severe genetic disorders. Proceeds from the Series D will be used by Encoded to conduct clinical trial activities, including a natural history study to better understand the progression of SCN1A+ Dravet Syndrome, as well as first-in-human trials for ETX101, the company’s lead asset, which was granted Orphan Drug Designation and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration for the treatment of SCN1A+ Dravet Syndrome.

The financing was led by GV (formerly Google Ventures) with participation from Matrix Capital Management, ARCH Venture Partners, Illumina Ventures, RTW Investments, Boxer Capital, Nolan Capital, HBM Genomics, Menlo Ventures, Meritech Capital, Farallon Capital Management, SoftBank Vision Fund 2, and additional investors.

The Wilson Sonsini team advising Encoded includes partners Ken Clark and Christina Poulsen, and associates Jonathan Chan, Travis Scheft, and Helen Qi. 

Please see Encoded’s press release for more information.